Losartan but not enalaprilat acutely reduces reperfusion venticular tachyarrhythmias in hypertrophied rat hearts after low-flow ischaemia

Journal of Pharmacy and Pharmacology

Volumn 56, Issue 4, 2004, Pages 521-528

  Butz, Silvia ^a   Driamov, Sergey ^a   Remondino, Andrea ^a   Bellahcene, Mohamed ^a   Beier, Konstantin ^b   Ziegler, André ^a   Buser, Peter T ^a   Zaugg, Christian E ^a  

^a UNIVERSITY HOSPITAL BASEL   (Switzerland)

^b UNIVERSITY OF BASEL   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

AMIODARONE; ENALAPRILAT; LOSARTAN; RAPIDOCAINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIARRHYTHMIC ACTIVITY; AORTA COARCTATION; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DISEASE DURATION; DOSE RESPONSE; HEART MUSCLE ISCHEMIA; HEART MUSCLE POTENTIAL; HEART PERFUSION; HEART REPOLARIZATION; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE HYPERTROPHY; HEART VENTRICLE TACHYCARDIA; ISOLATED HEART; MALE; NONHUMAN; RAT; REPERFUSION INJURY;

ACTION POTENTIALS; ANIMALS; ANTI-ARRHYTHMIA AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ENALAPRILAT; HEART; HYPERTROPHY, LEFT VENTRICULAR; LOSARTAN; MALE; RATS; RATS, SPRAGUE-DAWLEY; REPERFUSION INJURY; TACHYCARDIA, VENTRICULAR; VENTRICULAR FIBRILLATION;

EID: 1842418823     PISSN: 00223573     EISSN: None     Source Type: Journal    
DOI: 10.1211/0022357023178     Document Type: Article

References (41)

1. Aronson, R. S., Ming, Z. (1993) Cellular mechanisms of arrhythmias in hypertrophied and failing myocardium. Circulation 87: 76-83
2. Birincioglu, M., Aksoy, T., Olmez, E., Acet, A. (1997) Protective effect of ACE inhibitors on ischemia-reperfusion-induced arrhythmias in rats: Is this effect related to the free radical scavenging action of these drugs? Free Radic. Res. 27: 389-396
3. Caballero, R., Delpon, E., Valenzuela, C., Longobardo, M., Tamargo, J. (2000) Losartan and its metabolite E3174 modify cardiac delayed rectifier K(+) currents. Circulation 101: 1199-1205
4. Cerbai, E., Barbieri, M., Li, Q., Mugelli, A. (1994) Ionic basis of action potential prolongation of hypertrophied cardiac myocytes isolated from hypertensive rats of different ages. Cardiovasc. Res. 28: 1180-1187
5. Christ, D. D. (1995) Human plasma protein binding of the angiotensin II receptor antagonist losartan potassium (DuP 753/MK 954) and its pharmacologically active metabolite EXP3174. J. Clin. Pharmacol. 35: 515-520
6. Curtis, M. J. (1998) Characterisation, utilisation and clinical relevance of isolated perfused heart models of ischaemia-induced ventricular fibrillation. Cardiovasc. Res. 39: 194-215
7. De Mello, W. C. (2001) Cardiac arrhythmias: The possible role of the renin-angiotensin system. J. Mol. Med. 79: 103-108
8. De Mello, W. C., Crespo, M. J. (1999) Correlation between changes in morphology, electrical properties, and angiotensin-converting enzyme activity in the failing heart. Eur. J. Pharmacol. 378: 187-194
9. Donmez, G., Derici, U., Erbas, D., Arinsoy, T., Onk, A., Sindel, S., Hasanoglu, E. (2002) The effects of losartan and enalapril therapies on the levels of nitric oxide, malondialdehyde, and glutathione in patients with essential hypertension. Jpn. J. Physiol. 52: 435-440
10. Fleetwood, G., Boutinet, S., Meier, M., Wood, J. M. (1991) Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart. J. Cardiovasc. Pharmacol. 17: 351-356
11. Furukawa, T., Moroe, K., Mayrovitz, H. N., Sampsell, R., Furukawa, N., Myerburg, R. J. (1991) Arrhythmogenic effects of graded coronary blood flow reductions superimposed on prior myocardial infarction in dogs. Circulation 84: 368-377
12. Gilat, E., Girouard, S. D., Pastore, J. M., Laurita, K. R., Rosenbaum, D. S. (1998) Angiotensin-converting enzyme inhibition produces electrophysiologic but not antiarrhythmic effects in the intact heart. J. Cardiovasc. Pharmacol. 31: 734-740
13. Grover, G. J., Sleph, P. G., Dzwonczyk, S., Wang, P., Fung, W., Tobias, D., Cushman, D. W. (1991) Effects of different angiotensin-converting enzyme (ACE) inhibitors on ischemic isolated rat hearts: Relationship between cardiac ACE inhibition and cardioprotection. J. Pharmacol. Exp. Ther. 257: 919-929
14. Kohya, T., Yokoshiki, H., Tohse, N., Kanno, M., Nakaya, H., Saito, H., Kitabatake, A. (1995) Regression of left ventricular hypertrophy prevents ischemia-induced lethal arrhythmias. Beneficial effect of angiotensin II blockade. Circ. Res. 76: 892-899
15. Lee, Y. M., Peng, Y. Y., Ding, Y. A., Yen, M. H. (1997) Losartan attenuates myocardial ischemia-induced ventricular arrhythmias and reperfusion injury in spontaneously hypertensive rats. Am. J. Hypertens. 10: 852-858
16. Lynch, J. J., Stump, G. L., Wallace, A. A., Painter, C. A., Thomas, J. M., Kusma, S. E., Gould, R. J., Grossman, W. (1999) EXP3174, the AII antagonist human metabolite of losartan, but not losartan nor the angiotensin-converting enzyme inhibitor captopril, prevents the development of lethal ischemic ventricular arrhythmias in a canine model of recent myocardial infarction. J. Am. Coll. Cardiol. 34: 876-884
17. Matsuo, K., Kumagai, K., Annoura, M., Yamanouchi, Y., Handa, K., Nakashima, Y., Hiroki, T., Arakawa, K. (1997) Effects of an angiotensin II antagonist on reperfusion arrhythmias in dogs. Pacing Clin. Electrophysiol. 20: 938-945
18. Messerli, F. H. (1999) Hypertension and sudden cardiac death. Am. J. Hypertens. 12: 181S-188S
19. Najib, N. M., Idkaidek, N., Adel, A., Admour, I., Astigarraga, R. E., De Nucci, G., Alam, S. M., Dham, R. (2003) Bioequivalence evaluation of two brands of enalapril 20 mg tablets (Narapril and Renitec) in healthy human volunteers. Biopharm. Drug Dispos. 24: 315-320
20. Ozer, M. K., Sahna, E., Birincioglu, M., Acet, A. (2002) Effects of captopril and losartan on myocardial ischemia-reperfusion induced arrhythmias and necrosis in rats. Pharmacol. Res. 45: 257-263
21. Pitt, B., Segal, R., Martinez, F. A., Meurers, G., Cowley, A. J., Thomas, I., Deedwania, P. C., Ney, D. E., Snavely, D. B., Chang, P. I. (1997) Randomised trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in the Elderly Study, ELITE). Lancet 349: 747-752
22. Pitt, B., Poole-Wilson, P. A., Segal, R., Martinez, F. A., Dickstein, K., Camm, A. J., Konstam, M. A., Riegger, G., Klinger, G. H., Neaton, J., Sharma, D., Thiyagarajan, B. (2000) Effect of losartan compared with captopril on mortality in patients with symptomatic heart failure: Randomised trial - the Losartan Heart Failure Survival Study ELITE II. Lancet 355: 1582-1587
23. Rochetaing, A., Barbe, C., Kreher, P. (2001) Beneficial effects of amiodarone and dronedarone (SR 33589b), when applied during low-flow ischemia, on arrhythmia and functional parameters asssessed during reperfusion in isolated rat hearts. J. Cardiovasc. Pharmacol. 38: 500-511
24. Rump, L. C., Oberhauser, V., Schwertfeger, E., Schollmeyer, P. (1998) Experimental evidence to support ELITE. Lancet 351: 644-645
25. Stevenson, W. G., Stevenson, L. W., Middlekauf, H. R., Saxon, L. A. (1993) Sudden death prevention in patients with advanced ventricular dysfunction. Circulation 88: 2953-2961
26. Stevenson, W. G., Middlekauf, H. R., Saxon, L. R. (1995) Ventricular arrhythmias in heart failure. In: Zipes, D. P., Jalife, J. (eds) Cardiac electrophysiology. From cell to bedside. W. B. Saunders Company, Philadelphia, pp 848-863
27. Thomas, G. P., Ferrier, G. R., Howlett, S. E. (1996) Losartan exerts antiarrhythmic activity independent of angiotensin II receptor blockade in simulated ventricular ischemia and reperfusion. J. Pharmacol. Exp. Ther. 278: 1090-1097
28. Timmermans, P. B., Smith, R. D. (1994) Angiotensin II receptor subtypes: Selective antagonists and functional correlates. Eur. Heart J. 15 (Suppl. D): 79-87
29. Timmermans, P. B., Wong, P. C., Chiu, A. T., Herblin, W. F., Benfield, P., Carini, D. J., Lee, R. J., Wexler, R. R., Saye, J. A., Smith, R. D. (1993) Angiotensin II receptors and angiotensin II receptor antagonists. Pharmacol. Rev. 45: 205-251
30. Vakili, B. A., Okin, P. M., Devereux, R. B. (2001) Prognostic implications of left ventricular hypertrophy. Am. Heart J. 141: 334-341
31. Van Tyn, R. A., MacLean, L. D. (1961) Ventricular fibrillation threshold. Am. J. Physiol. 201: 457-461
32. Velleman, P., Hoaglin, D. (1981) Applications, basics, and computing of exploratory data analysis. Duxbury Press, Boston
33. Viswanathan, P. C., Shaw, R. M., Rudy, Y. (1999) Effects of IKr and IKs heterogeneity on action potential duration and its rate dependence: A simulation study. Circulation 99: 2466-2474
34. Walker, M. J., Curtis, M. J., Hearse, D. J., Campbell, R. W., Janse, M. J., Yellon, D. M., Cobbe, S. M., Coker, S. J., Harness, J. B., Harron, D. W., Higgins, A. J., Julian, D. G., Lab, M. J., Manning, A. S., Northover, B. J., Parratt, J. R., Riemersma, R. A., Riva, E., Russell, D. C., Sheridan, D. J., Winslow, E., Woodward, B. (1988) The Lambeth Conventions: Guidelines for the study of arrhythmias in ischaemia infarction, and reperfusion. Cardiovasc. Res. 22: 447-455
35. Yahiro, E., Ideishi, M., Wang, L. X., Urata, H., Kumagai, K., Arakawa, K., Saku, K. (2003) Reperfusion-induced arrhythmias are suppressed by inhibition of the angiotensin II type I receptor. Cardiology 99: 61-67
36. Yasar, U., Forslund-Bergengren, C., Tybring, G., Dorado, P., Llerena, A., Sjoqvist, F., Eliasson, E., Dahl, M. L. (2002) Pharmacokinetics of losartan and its metabolite E-3174 in relation to the CYP2C9 genotype. Clin. Pharmacol. Ther. 71; 89-98
37. Zaugg, C. E., Wu, S. T., Lee, R. J., Parmley, W. W., Buser, P. T., Wikman-Coffelt, J. (1996a) Importance of calcium for the vulnerability to ventricular fibrillation detected by premature ventricular stimulation: Single pulse versus sequential pulse methods. J. Mol. Cell. Cardiol. 28: 1059-1072
38. Zaugg, C. E., Hornstein, P. S., Zhu, P., Simper, D., Luscher, T. F., Allegrini, P. R., Buser, P. T. (1996b) Endothelin-1-induced release of thromboxane A2 increases the vasoconstrictor effect of endothelin-1 in postischemic reperfused rat hearts. Circulation 94: 742-747
39. Zhu, P., Zaugg, C. E., Hornstein, P. S., Allegrini, P. R., Buser, P. T. (1999) Bradykinin-dependent cardioprotective effects of losartan against ischemia and reperfusion in rat hearts. J Cardiovasc. Pharmacol. 33: 785-790
40. Zhu, B., Sun, Y., Sievers, R. E., Browne, A. E., Pulukurthy, S., Sudhir, K., Lee, R. J., Chou, T. M., Chatterjee, K., Parmley, W. W. (2000) Comparative effects of pretreatment with captopril and losartan on cardiovascular protection in a rat model of ischemia-reperfusion. J. Am. Coll. Cardiol. 35: 787-795
41. Ziegler, A., Zaugg, C. E., Buser, P. T., Seelig, J., Kunnecke, B. (2002) Non-invasive measurements of myocardial carbon metabolism using in vivo 13C NMR spectroscopy. NMR Biomed. 15: 222-234